Harrow, Inc Investor Event Transcript, Nov 18, 2026
Harrow, Inc. (HROW)
Harrow reported record third-quarter revenue of better than $99 million. It guided revenue of between $350 and $365 million this year and fourth-quarter adjusted EBITDA of better than $33 million. AI summary
Conference Transcript - HROW 2026-11-18
Operator
Good morning, everyone. Welcome to the 2026 Jefferies Healthcare Conference. This morning, we're very pleased to have Mark Baum, CEO of HARO. Thank you very much.
Mark L. Baum, CEO
Thank you, and I want to thank our friends at Jeffrey's. We really appreciate this audience. I know it's 8 a.m. if you're from the States. It's even earlier. Many of you haven't had your second or third cups of coffee, but you're investors, so I'm going to try and stimulate you in a different way by talking about Three value drivers for Harrow. The first is the growth that we've delivered and that we are delivering. The second is the operating leverage that's now showing up in our business. And the third is the opportunity to really accelerate our growth in the coming years. And towards the end of the presentation, I actually have a special surprise that I'm going to provide to the audience. So stay tuned. So, Harrow's in the ophthalmic pharmaceutical business. We focus on the U.S. market, and we now have the broadest portfolio, the largest portfolio of prescription eye care products for the U.S. market. There are three core brands that we're going to talk about today that are the primary drivers of our growth. And they're all in early stages of their growth. And then finally, we've built a commercial platform, bought, it's paid for, it is deployed, and it is structured for us to actually add additional products onto for the same exact call point that these teams call on day in and day out. So here's a look at our financials. As you can see, we've grown nicely over the last five years. We have a five-year revenue CAGR of better than 40%, a five-year adjusted EBITDA CAGR of better than 60%. We've guided that we'll do between $350 and $365 million this year. The midpoint is $357.5 million, and that's up from $272.3 million last year. We've guided that in the fourth quarter, we'll do better than $33 million in adjusted EBITDA, and that's up from the $21.2 million that we recently reported. The third quarter of this year was a record quarter for HARO. We did better than $99 million, just a whisker under $100 million in revenue. Eighty-three and a half million of which was branded revenue with a gross margin profile of nearly 80%. We have about $75 million in cash in the bank at the end of the period, and we do have $300 million in unsecured notes that bear an eight and five-eighths coupon that are due in about four years. So let's jump into those three pillars of growth that I discussed. The first... is the growth that we have delivered and that we are intending to continue to deliver. So, let's talk about those three products. The first is Vivi. Vivi is a dry eye disease product, and in the third quarter, it did nearly $40 million in revenue. That was 75% growth in the third quarter over the prior year's third quarter. Prescriptions for Vivi were up 83% year-over-year. Aihizo... It's a unique patented ocular anesthetic that did over $25 million in revenue for the quarter. That was 15% growth in revenue with unit demands up 21%. I'm going to drill down a little bit more into IHESO specifically in a few minutes because the performance of that product was actually better, I think, than these numbers even indicate. And then finally, triessence is an injectable steroid. It's used in ocular surgery. That's the primary market, and it is growing rapidly. Finally did better than $10 million in revenue for the quarterly period, growing beautifully, 186 percent growth in revenue with unit demand up 110 percent. In the aggregate, those three products make up about $75 million of our revenue. That's 76% of our total and 91% of our branded revenue. So let's look a little bit deeper at the specific products. Viva in particular serves the dry eye market. It's a very large market in the U.S. More than 38 million Americans suffer from Dry eye symptoms. However, only a little over a million patients are on prescription therapy, but the category is growing nicely. In fact, it's grown at better than 20% a year for the past two years. How do we participate in the market, that growing market? With Vivi, which is the only water-free cyclosporine, which is an anti-inflammatory, in the dry eye disease category. It doesn't contain water. What does that mean? It has a unique vehicle that uniquely is able to deliver cyclosporine more efficiently than any other vehicle that we know of. In fact, it delivers about 22 times the amount of cyclosporine to the site and source of inflammation than does the vehicle in, for example, Restasis, which may be a product that you're familiar with. The drug works very quickly in as little as 15 days, and if you've ever put it on your eye, you know that it feels good when you put it on your eye, Which is different than many of the other competing products in the category that burn or sting or can cause dyscusia, give you a bad taste in your mouth. And we have good IP out into the late 2030s, 2039. In terms of the performance of the product, as I said, record revenues in the third quarter, we did just under $40 million in revenue, prescription growth up 83%, sequential quarterly revenue growth of 35%, and we've made an investment in this program because we really believe in it. We've increased the size of the sales organization from the beginning of the year to the present time about three-fold, and we continue to get more and more coverage for Vivi. In fact, on January 1st, we've got 10.7 million new commercial lives that we will have access to. When we evaluate a product like Vivi, we really look at three main factors to think about the health. The first is net pricing, the second is total prescriptions, and the third is insurance coverage, and the ratio of patients that are paying cash versus seeking insurance for their prescriptions. And in all three of those categories, total prescriptions, net pricing, and insurance access, Vivi is improving and on the rise. The second of our products that I want to talk about is Ihezo, which is a patented, reimbursable, topical anesthetic for the U.S. market, and uniquely, it is the only reimbursable product in the U.S. eye care market. If you're going to poke on the eye, inject something to the eye, or cut on the eye, you need to anesthetize the eye, obviously. Ihezo, as I said, is the only product currently in the market that is reimbursable. It has a product-specific permanent J-code. Now, I mentioned that unit demand was up 21%, and that may be a little bit of a misnomer in terms of the actual performance of the product this year, and I want to elaborate a little bit more on what I mean. At the beginning of this year, we sold IHIZO into two markets, two distinct customers. One was the cataract surgery market, where we sold to the cataract surgeons. It was used to anesthetize the eye for cataract surgeries. And the second market was for intravitreal injections, whether you're injecting ILEA, Lucentis, Vibizmo. We really didn't care what you were injecting as long as you anesthetized the eye with IHESO. Both of those markets. We're being served by IHESO. However, at the end of the first quarter of 2026, we lost our pass-through status, and so the entire cataract surgery market, that outreach to the cataract surgeon, completely went away. And what I think is interesting and telling about the health of the brand is that despite losing more than 20% of the unit demand for IHESO after we lost pass-through, we still managed in the third quarter to have 21% growth in that franchise in terms of unit demand in the third quarter of 2026 versus 2025. But what does that all mean for the future, if you're an investor in Hero? It means a couple of things, because on July 1st, we were able to actually see a 25% increase in our net price, and we're in the fourth quarter. The fourth quarter is historically the strongest quarter for this product, and I believe it will be the strongest quarter in the history of our selling IHIZO. It's also going to be buttressed, our sales efforts, that is, by some recent data that we invested in called the QUELL study, which demonstrated that if you use IHESO as opposed to standard of care anesthesia, patients... Immediately after an injection of lidocaine versus our topical anesthetic have essentially the same level of pain, two out of five. However, after that fourth hour and up to 24 hours, if you use the topical anesthetic as opposed to the standard of care, which is an injection of lidocaine, you actually have less pain, less ocular surface damage, and fewer adverse events. So great data to help us increase the unit volumes of IHISO going forward. Now, Triessence has been a great story for us, and it's now starting to show in the third quarter. Recall that this is an injectable steroid. It was purchased by us from Novartis, and at the time that we purchased it, it really was not available for most of the prior five years. It wasn't in stock for ophthalmologists to get access to. We acquired it. We fixed the supply chain. We actually fixed the coating and reimbursement for the product, and we began to sell the product on the entirety of the label. And now you see the demand showing up. We did have a record quarter for triessence, better than $10 million in revenue, but it's a big market opportunity, not only for surgical inflammation, but also other retina indications as well that are in office. The product has tremendous coverage, better than 95% coverage, and for the patient, a very low out-of-pocket at around $38 out-of-pocket. We really believe strongly in TriEssence, and we're investing in TriEssence, this brand. We have a cataract surgery phase four study that's going to read out in the first half of 2027, and we've invested in a next generation version of this product that we're going to file, hopefully we'll file an NDA on in 2027 and launch in 2028 or early 2029. So, big market opportunity. It's a high-trust product, great reimbursement, low out-of-pocket. We believe strongly in what we're doing for this community with Triessence. So operating leverage. We have a great platform that we've built. But now, interestingly, our revenues are growing faster than our cost structure, and this is what I mean by operating leverage. We have four commercial teams. We have an ocular surface team that is focused on selling Vivi. We have a retina team that is focused on selling Ihezo, and then a surgical team that is focused on our triessence brain. We also have a fourth team called Access Plus that only focuses on compounded medications. But here's what I mean by operating leverage. If you look at SG&A. As a percentage of revenue, in the first half of this year, it was 84%. However, in the third quarter, it went down to 54%. Third quarter revenue rose 41%, yet our cost structure did not... Markedly increase, and that's shown on this bar chart on this next slide. So you see that we had flat SG&A from Q2 to Q3. We also had an increase in revenue of about $28 million, $22 million of which. Went to the profit line. So 78% of that was converted. So we don't expect, as we continue to grow, to see that cost structure increase, not nearly at the same rate as our revenues are expected to increase. And that's what we mean by operating leverage now showing up in the business model. And in fact, over the coming quarters, those percentages might even rise. So, we have these core products. They're a significant portion of our branded revenue. We have this commercial infrastructure that we've invested in, we've built, we've deployed, and now we are set to actually accelerate our growth. We have new products that we intend to launch in growing categories over the coming years. In fact, we'll have one product launch every year into 2030, and each of those products will fit within the existing commercial teams that we've already deployed, and that should not only accelerate our growth but also increase this operating leverage concept. This is what I mean by new products each year into 2030. So I mentioned the ocular surface team, they focus on selling Vivi, but we recently acquired Terviya from Vietris, and in the fourth quarter, it is now producing revenue for Harrow. And next year, It will produce more than $30 million of revenue for Harrow. Once again, being sold by that same ocular surface disease team that's focused on Vivi. No additional infrastructure costs, SG&A costs, for that. And on the retina side of things, that team's focused on IHESO. We've already launched BioViz, which is our Lucentis reference biosimilar that launched July 1st. It's having a pretty strong fourth quarter, by the way. But next year, we intend to launch Opiviz, which is our ILEA 2-MIG biosimilar that will also be sold through the retina team to the same call point that they call on day in and day out. And then finally, our surgical team that focuses on Triessence is launching by Clovey this quarter and will launch, hopefully in 2028, G-Melt, which I'm going to talk about shortly, and then, of course, our next generation version of Triessence. So, you see that the teams are there. They're calling on these doctors, and we can add to their bags without disrupting their ability to be effective with their primary products. And this is just an illustration of what I meant by products that are delivering revenue that is currently effective. So, Treviya is a dry eye disease nasal spray, and that is being sold by our ocular surface team, BioViz, and OpioViz, as I said, through our retina team. Now, I'm going to talk to you about G-Melt, which is an exciting product that we're going to hopefully file an NDA on in the coming weeks. G-Melt began with a phone call that I received from a cataract surgeon over 10 years ago who was interested in sedating cataract surgery patients without IVs and without opioids. Believe it or not, in the U.S., Nine out of ten of these cataract surgeries involved the administration of fentanyl in order to sedate patients for cataract surgery, and his idea was to, as I said, eliminate the IV and eliminate the opioids, and so we built a compounded product for him. We began to sell it into the market, and it started with one doctor, and that one became 10, and the 10 became 100. And all of a sudden, we had over 800 institutions using the compounded version of the product. Then... Dermatologists called us. Dentists called us. ENTs called us. Other specialties and sub-specialties were interested in sedating their patients using this compounded version of what we're going to talk about, which is called the G-Melt. We decided to seek FDA approval for it and run a traditional regulatory program for, as I said, what we now call G-Melt. Thank you. In the next couple of weeks, we intend to file an NDA on this product, and hopefully we'll have a label to sedate patients for cataract surgery in the U.S. market, and then over the coming years, we can invest in expanding the label for other opportunities and indications, because the need for procedural sedation medicaments is significant. Again, it's more than 100 million annual procedures in the U.S. market alone, but we're starting off with the cataract surgery. So I did promise you a special gift. While I was here in London, yesterday we arrived, I went out to visit our partner, which is Catalan. We deliver this sublingual sedation medication, the G-Melt, using a technology that they have called Zytus. And you can imagine if you're a cataract surgery patient, you're going in for the procedure, you're worried about your vision post-procedure, you're worried about maybe getting an IV, you may be worried about getting an opioid. This is an opportunity to reduce or eliminate those exposures, and so our friends at Catalan actually gave us some samples of the Zytus technology. These don't have active ingredient in them, but I'm going to ask Andrew to pass them around. They're actually breath mints, and you can put them under your tongue and experience what it feels like to have this Zytus technology under your tongue, And you can see how fast the tablet melts away. It's literally in a matter of three to five seconds. So, we're really excited about the G-Melt, we're excited to file the NDA, and we're really excited to offer our 800-plus institutional customers that currently buy the compounded version of the product to have now an FDA-approved, hopefully reimbursable version of this product. So. The catalysts for HARO are significant this year and in 2028, 2029, and 2030 as we continue to launch more products and get operating leverage from our commercial infrastructure and hopefully accelerate our growth. We are going to have an investor day in New York in the spring. We hope to talk about our triessence data then. In January, we're actually going to discuss the full results of our Quell study, and a lot of interesting things happening next year, I think, that will act as catalysts for the business, and not the least of which is having our PDUFA date for the G-Melt. So I hope you'll all agree that we've delivered growth. We continue to deliver growth. We are seeing operating leverage show up in our business, and we do have the opportunity to meaningfully accelerate our growth as we launch additional products and growing categories through our commercial infrastructure year, each year through 2030. Finally, I'll just say that... There was a quote in my last stockholder letter. I said, I saw a disconnect between the stock's performance and the value that the team has worked so hard to create, and I do want to say that for us, for our team, we're focused on consistent operational execution. If you're a shareholder in HARO, know that the entire HARO family is focused on operational execution, and we believe that is the only remedy, really, for healing this disconnect, which we intend to do. Thank you very much.